📮 Tensor Ventures — Decoded Newsletter August 2025 Edition
Welcome back from the summer break! Hot Girl Summer is over, and we’re entering Deep Tech Autumn. 🍂 Here’s the latest from Tensor in August with major news:
🚀 Portfolio in Action
Quantagonia successfully exited to a U.S. company, marking another milestone for Tensor’s quantum investments.
Aireen secured a new investment round, fueling the next stage of its growth in digital health.
Sifted featured BEIT’s CEO & Co-founder Paulina Mazurek among 8 female founders to watch in quantum, highlighting another strong voice in our portfolio.
Edmund continues building momentum in AI-driven infrastructure, setting new standards for efficiency and scale.
QuireGen is pushing forward with its mission to revolutionize drug discovery.
Meanwhile, dstack’s hosting a hands-on developer event in SF, showcasing open-source tools for AI infra. Join here.
👉 For more updates, follow us on LinkedIn.
👩🏽💻 Deep tech scene
IBM & AMD Collaborate on Quantum-Centric Supercomputing
IBM and AMD announced a joint initiative to build next-generation computing architectures that merge quantum computers with high-performance classical computing and AI accelerators. The goal is to enable hybrid systems that can tackle problems beyond either paradigm alone.
QuamCore Raises $26M to Pursue 1-Million-Qubit Quantum Ambition
QuamCore secured a Series A raise of $26 million to work on a 1-million-qubit quantum computer in a single cryostat. It’s an audacious scaling goal and signals strong investor confidence in quantum hardware advances.
Top Biotech Deals in August 2025: Small Molecules, Antibodies & Royalty Models.
The biotech space had a busy month. Big pharma made several key acquisitions and partnerships:
AbbVie acquired Gilgamesh Pharmaceuticals for ~$1.2B to take control of a novel psychedelic therapy.
Xoma Royalty and others struck royalty interest deals, and Interius BioTherapeutics was acquired by Kite to bolster its CAR-T pipeline.
The trends show that small molecules, RNA, and creative royalty financing are very much in play
ChronicleBio’s Push on Neuroimmune Tech
ChronicleBio (a tech-bio startup) announced its mission to accelerate insight into neuroimmune disorders, combining deep tech and biomedical science expertise. It’s emblematic of the growing intersection between tech, AI, and biology.Fujitsu Eyes +10,000-Qubit Superconducting Quantum Computer
Fujitsu announced R&D work toward a superconducting quantum computer exceeding 10,000 qubits, targeting fiscal 2030 to have an operational system. This includes a “STAR architecture” for early fault tolerance and is part of Japan’s push toward industrialized quantum.
📣 Events / On Our Radar
Petr Ulvr joined Jan Kavalírek and Robert K. on the panel “Czech AI: From Strategy to Execution” to discuss how our country can transform AI ambitions into real-world impact.
Meanwhile, Jan was at the AI side chat by Tech Europe in Berlin 🙌🏼
👋🏼 Catch us at Prague.bio conference 2025 this week - and at How to web and Bits & Pretzels next month.
Cheers,
The Tensor VC team